FENNEC PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Unrealized Loss
FENNEC PHARMACEUTICALS INC. (FENC) reported Debt Securities, Available-for-sale, Unrealized Loss of $2.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-13
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $1.00K.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-03-31 was $1.00K, a 90.91% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for fiscal 2025 was $2.00K, a 97.53% decline from fiscal 2024.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $81.00K, a 107.69% increase from fiscal 2023.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $39.00K, a 78.80% decline from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $184.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $1.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00K derived: sum of 2 quarters · filed 2026-08-13 | $2.00K 10-Q · filed 2025-11-13 | $69.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.00K 10-Q · filed 2026-08-13 | $69.00K derived: sum of 3 quarters · filed 2026-08-13 | $72.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-14 | $68.00K derived: sum of 2 quarters · filed 2026-05-14 | $71.00K derived: sum of 3 quarters · filed 2026-05-14 | $71.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $70.00K derived: sum of 2 quarters · filed 2026-03-27 | $70.00K derived: sum of 3 quarters · filed 2026-03-27 | $81.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $3.00K 10-Q · filed 2024-11-08 | $3.00K derived: sum of 2 quarters · filed 2025-08-14 | $14.00K 10-Q · filed 2025-11-13 | $10.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $11.00K 10-Q · filed 2025-08-14 | $7.00K derived: sum of 3 quarters · filed 2025-08-14 | $20.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.00K 10-Q · filed 2025-05-14 | $7.00K derived: sum of 2 quarters · filed 2025-05-14 | $20.00K derived: sum of 3 quarters · filed 2025-05-14 | $20.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $9.00K derived: sum of 2 quarters · filed 2025-03-26 | $9.00K derived: sum of 3 quarters · filed 2025-03-26 | $39.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $13.00K 10-Q · filed 2024-11-08 | $13.00K derived: sum of 2 quarters · filed 2024-11-08 | $43.00K 10-Q · filed 2024-11-08 | $101.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $30.00K 10-Q · filed 2024-08-13 | $88.00K derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $30.00K 10-Q · filed 2024-05-14 | $88.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $184.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $126.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |